Sep 9, 2015 8:00 am EDT VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial
Sep 2, 2015 8:00 am EDT VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015
Sep 1, 2015 8:00 am EDT VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015
Aug 17, 2015 8:00 am EDT VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer
Aug 11, 2015 6:30 am EDT VolitionRx Announces Second Quarter 2015 Financial Results and Business Update
Aug 5, 2015 8:00 am EDT VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET
Jul 27, 2015 8:00 am EDT VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs
